Beta Bionics (BBNX) Stock Price, News & Analysis

Company Overview

Beta Bionics, Inc. is a medical technology company focused on the development and commercialization of automated insulin delivery systems for people with insulin-dependent diabetes. The company’s core mission is to simplify glycemic management through advanced robotics and algorithm-driven platforms. Beta Bionics leverages proprietary adaptive control algorithms to continuously adjust insulin dosing in real time, aiming to reduce hypoglycemic and hyperglycemic events while easing the burden of daily diabetes management.

The company’s lead product candidate, the iLet Bionic Pancreas System, integrates wearable hardware with a bi-hormonal or insulin-only configuration and communicates seamlessly with a disposable infusion set. In clinical trials, the iLet system has demonstrated the ability to autonomously manage blood glucose levels with minimal user input, drawing upon years of research collaborations with Massachusetts General Hospital and Boston University. Beta Bionics is actively pursuing regulatory approvals in the United States and Europe, positioning the iLet platform for broad adoption among adults and pediatrics with type 1 diabetes.

Founded in 2015 and headquartered in Boston, Massachusetts, Beta Bionics operates research and development facilities in key biotech hubs across North America and Europe. The company has attracted strategic partnerships and grant funding from leading diabetes advocacy groups, academic institutions, and technology firms. Under the leadership of Chief Executive Officer Justin McAnear and co-founder Dr. Edward Damiano—an engineer and diabetes technology pioneer—Beta Bionics continues to expand its clinical program and manufacturing capabilities. The management team is supported by a board of directors and medical advisory board comprising endocrinologists, engineers, and patient advocates dedicated to advancing closed-loop diabetes solutions.

Key Stats

• Today's Range: $13.17 to $14.35
• 50-Day Range: $10.80 to $19.55
• 52-Week Range: $8.89 to $24.50
• Volume: 121,291 shs
• Average Volume: 500,194 shs
• Market Capitalization: $586.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.44
• Consensus Rating: Moderate Buy

BBNX Stock Analysis - Frequently Asked Questions

How have BBNX shares performed this year?

Beta Bionics' stock was trading at $23.81 on January 1st, 2025. Since then, BBNX stock has decreased by 43.2% and is now trading at $13.52.

How were Beta Bionics' earnings last quarter?

Beta Bionics, Inc. (NASDAQ:BBNX) released its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.01.
Read the conference call transcript.

When did Beta Bionics IPO?

Beta Bionics (BBNX) raised $204 million in an initial public offering (IPO) on Thursday, January 30th 2025. The company issued 12,000,000 shares at a price of $17.00 per share.

When does the company's lock-up period expire?

Beta Bionics's lock-up period expires on Tuesday, July 29th. Beta Bionics had issued 12,000,000 shares in its initial public offering on January 30th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. After the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Beta Bionics?

Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBNX
• Previous Symbol: NASDAQ:BBNX
• CIK: 1674632
• Web: N/A
• Phone: (949) 427-7785
• Fax: N/A
• Employees: 294
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.44
• High Stock Price Target: $30.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +73.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.88
• Quick Ratio: 14.93

Sales & Book Value

• Annual Sales: $65.12 million
• Price / Sales: 9.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.72) per share
• Price / Book: -2.36

Miscellaneous

• Outstanding Shares: 43,360,000
• Free Float: N/A
• Market Cap: $586.23 million
• Optionable: N/A
• Beta: N/A